Hematological Diseases and Therapies
ISSN: 2577-1418 Impact Factor: 3.02

Synchronous Pneumonitis, Hepatitis and Enteritis Under Treatment with PI3kδ Inhibitor Idelalisib for Follicular Lymphoma

by Maria Vergoulidou*, Diana Japaridze, Norbert Grobe

  • Published
  • Volume 3
  • Issue 2
  • ISSN 2577-1418
  • Reads 864
Download PDF

Maria Vergoulidou*, Diana Japaridze, Norbert Grobe

First Internal Medicine Department, Hematology and Oncology, Dietrich Bonhoeffer Klinikum Neubrandenburg, Germany

*Corresponding author: Maria Vergoulidou, First Internal Medicine Department, Hematology and Oncology, Dietrich Bonhoeffer Klinikum Neubrandenburg, Germany. Email: marivergi@yahoo.com

Received Date: 30 May, 2018; Accepted Date: 10 June, 2018; Published Date: 19 June, 2018

1.                   Abstract

Idelalisib is approved for the treatment of relapsed follicular lymphoma. We report a case with multiple toxicities during treatment including pneumonitis, hepatitis and enteritis. Toxicities resolved under supportive treatment. Idelalisib was discontinued.  Our patient achieved partial remission of follicular lymphoma and had no further late complications. 

2.                   Keywords: Enteritis; Follicular Lymphoma Case Report; Hepatitis, Idelalisib; Pneumonitis


Figure 1: Elevation of transaminases (ALAT: serum alanine, ASAT: aspartate aminotransferase). Normal range 0,17-0,85 μmol/l.



Figure 2: Chest CT showing interstitial infiltrates and bilateral basal ground-glass opacities (upper image) and their resolution after a 3-month period (lower image).


1.       Gopal AK, Kahl BS, de Vos S, Wagner-Johnston ND, Schuster SJ, et al. (2014) PI3Kdelta inhibition by idelalisib in patients with relapsed indolent lymphoma. N Engl J Med 370: 1008-1018.

2.    Gupta A, Li HC (2016) Idelalisib-induced pneumonitis. BMJ Case Rep 2016. Coutre SE, Barrientos JC, Brown JR, de Vos S, Furman RR, et al. (2015) Management of adverse events associated with idelalisib treatment: expert panel opinion. Leuk Lymphoma 56: 2779-2786.